Risk factors and occurrence of rash in HIV-positive patients not receiving nonnucleoside reverse transcriptase inhibitor: data from a randomized study evaluating use of protease inhibitors in nucleoside-experienced patients with very low CD4 levels (<50 cells/mmuL)

This publication has 10 references indexed in Scilit:

• Female sex but not ethnicity is a strong predictor of non-nucleoside reverse transcriptase inhibitor-induced rash
  AIDS, 2002
• Incidence of and Risk Factors for Severe Hepatotoxicity Associated with Antiretroviral Combination Therapy
  The Journal of Infectious Diseases, 2002
• Female sex and the use of anti-allergic agents increase the risk of developing cutaneous rash associated with nevirapine therapy
  AIDS, 2001
• Predictors of protease inhibitor-associated adverse events
  Biomedicine & Pharmacotherapy, 2001
• Sex Differences in Nevirapine Rash
  Clinical Infectious Diseases, 2001
• A Randomized Trial Comparing the Introduction of Ritonavir or Indinavir in 1251 Nucleoside-Experienced Patients with Advanced HIV Infection
  AIDS Research and Human Retroviruses, 2000
• Abacavir
  Drugs, 2000
• Is there cross-toxicity between nevirapine and efavirenz in subjects developing rash?
  AIDS, 2000
• Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients
  AIDS, 2000
• Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection
  Clinical Therapeutics, 1998